US regulator investigates tumour risk in Novartis gene therapy
The US FDA is investigating tumour risks associated with Novartis's gene therapy Zolgensma after nine cases emerged among treated infants.
The US FDA is investigating tumour risks associated with Novartis's gene therapy Zolgensma after nine cases emerged among treated infants.